Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL OF REGISTRATION APPLICATION FOR GEMS SERIES EMBRYO CULTURE MEDIUM (VITBASE EMBRYO PROCESSING FLUID)

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that on August 25, 2025, the Group obtained the Class III medical device registration certificate for its GEMS series embryo culture medium (VitBase embryo processing fluid) (registration certificate No.: Guo Xie Zhu Jin 20253180356) from the National Medical Products Administration of China (the "**NMPA**").

The Company's GEMS series embryo culture medium (VitBase embryo processing fluid) belongs to the GEMS series of culture medium developed by Genea Biomedx Pty Ltd. ("**Genea Biomedx**"), a wholly owned subsidiary of BMX Holdco Pte. Ltd., which is in turn wholly owned by the Company. This approval not only reflects China's support for the innovative transformation of overseas-acquired medical products but also positions the Company as one of the very few enterprises globally to simultaneously hold CE, FDA, and TGA certifications for assisted reproductive fluids, with a product line covering the entire assisted reproductive process.

For a long time, the core culture medium used in Chinese in vitro fertilization ("**IVF**") laboratories have primarily relied on overseas brands. As one of the critical factors influencing the success rate of IVF, the safety, stability, and long-term clinical validation data of culture media are of paramount importance to doctors and patients. The VitBase embryo processing fluid approved this time is built on over 30 years of clinical experience from Genea Biomedx. Combined with localized production and regulatory requirements, it maintains international standards of product quality while significantly enhancing accessibility and supply chain security.

The VitBase embryo processing fluid is the first product among the 11 culture mediums among the GEMS series embryo culture medium, which lays the foundation for the subsequent localization of the full range of culture media in China.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, August 26, 2025

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye, Mr. WANG Weipeng and Mr. LING Yang as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.